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PVIEWPOINT AND COMMENTARY
Dronedarone for Atrial Fibrillation
Have We Expanded the Antiarrhythmic Armamentarium?
David Singh, MD, Eugenio Cingolani, MD, George A. Diamond, MD, Sanjay Kaul, MD
Los Angeles, California
Dronedarone is a new antiarrhythmic agent that was recently approved for the prevention of cardiovascular hos-
pitalization driven by atrial fibrillation/flutter. Its approval was based largely on the results of the ATHENA (A
Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the
Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial
Flutter) trial, which demonstrated a significant 24% reduction in the combined end point of all-cause mortality
and cardiovascular hospitalization, primarily driven by the latter. However, several other clinical trials have evalu-
ated the impact of dronedarone on various cardiovascular end points and yielded mixed results. In this article,
we summarize the available evidence concerning dronedarone, and offer practical recommendations to health
care providers regarding its use in the treatment of atrial fibrillation. We conclude that the available data sup-
port the use of dronedarone in select patient populations as a second- or third-line agent. (J Am Coll Cardiol
2010;55:1569–76) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.071b
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(trial fibrillation (AF) is the most common sustained
rrhythmia in the U.S. (1), affecting nearly 2.3 million
atients and accounting for one-third (400,000) of all
atient discharges with arrhythmia as a principal diagnosis
2). The overall incidence of AF increases with each decade
f age, affecting nearly 6% of people over age 65 years.
early 71,000 patients die each year from the complications
f AF and atrial flutter (AFL) (2–4). Given the heavy
urden of AF on morbidity, mortality, and health care
esources, it is not surprising that the Institute of Medicine
as listed treatment of AF at the top of 100 priorities for
omparative effectiveness research as part of the American
ecovery and Reinvestment Act (ARRA) of 2009 (5).
Management of patients with AF/AFL has focused on 2
herapeutic strategies: a “rhythm-control strategy,” in which
ntiarrhythmic drugs are used along with electrical cardio-
ersion when necessary to restore normal sinus rhythm, and
“rate-control strategy,” in which no specific efforts are
ade to maintain sinus rhythm and slowing of the ventric-
lar response rate is the main objective. Data from random-
zed controlled trials have failed to establish superiority of
ither strategy over the other while demonstrating the
fficacy of both strategies in reducing symptoms and im-
roving the quality of life (6,7). Reduced efficacy and
ncreased toxicity of antiarrhythmic drugs likely contributed
o the lack of benefit observed with rhythm control. Driven
rom the Division of Cardiology, Cedars-Sinai Medical Center, and the David
effen School of Medicine, University of California, Los Angeles, California. Dr.
iamond is on the Speakers’ Panel of Merck.e
Manuscript received August 13, 2009; revised manuscript received September 29,
009, accepted October 5, 2009.y these circumstances, substantial resources have been
nvested in the development of new agents that minimize
oxicity while maintaining antiarrhythmic efficacy, and offer
mproved treatment options to patients in reducing morbid-
ty and mortality associated with AF/AFL. It is in this
ontext that the recent approval of dronedarone by the U.S.
ood and Drug Administration (FDA) for the “prevention
f cardiovascular hospitalization in patients with nonperma-
ent atrial fibrillation or atrial flutter” (8) has been enthu-
iastically received as having expanded the antiarrhythmic
rmamentarium (9). However, there are uncertainties with
espect to the drug’s efficacy and safety that merit careful
crutiny.
Dronedarone was specifically designed to overcome the
ide effects of its parent compound, amiodarone, while
aintaining its antiarrhythmic efficacy. Although amioda-
one has a longstanding track record for maintaining sinus
hythm, its use, particularly in higher doses, is limited by
dverse side effects, especially thyroid and pulmonary tox-
city. The electrophysiological properties of this new agent
10), which are similar to those of amiodarone, coupled with
he absence of iodine in its molecule, which is thought to
ender the drug less toxic, raised expectations that the new
rug might function as a safer alternative to amiodarone for
he treatment of AF (11).
Dronedarone is well absorbed after oral administration,
ith a bioavailability of approximately 15% after extensive
rst pass metabolism. As with amiodarone, the drug is
xtensively metabolized primarily by cytochrome P-450
CYP) 3A4 and excreted in the bile with minimal renal
xcretion (12). Thus, concurrent use of medications that
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Dronedarone for AF April 13, 2010:1569–76inhibit CYP3A4 can increase ex-
posure to the drug and result in
potentially serious drug-drug in-
teractions. Given that the drug is
highly bound to plasma proteins,
the steady-state terminal elimi-
nation half-life is approximately
30 h compared with the known
long half-life of amiodarone (ap-
proximately 58 days) due to ex-
tensive tissue deposition (12).
Like amiodarone, a 10% to 15%
increase in serum creatinine can
be seen with dronedarone; these
changes are related to inhibition
f tubular secretion of creatinine by the drug and do not
epresent a decrease in the glomerular filtration rate (12,13).
Several trials have investigated the efficacy and safety of
ronedarone. Four trials evaluated the efficacy in delaying or
educing recurrence of AF/AFL (12,14,15), 1 assessed the
mpact on rate control (16), and 2 assessed morbidity and
ortality outcomes (17,18) (Table 1). We herein review the
vidence from these trials focusing on dronedarone’s effi-
acy, safety, and tolerability, and provide recommendations
or its optimal use in clinical practice.
ntiarrhythmic Efficacy of Dronedarone
he antiarrhythmic efficacy of dronedarone has been eval-
ated in 4 placebo-controlled and 1 active-control random-
zed trials.
elay in recurrences of AF or maintenance of sinus
hythm. Data regarding the antiarrhythmic efficacy of
ronedarone are summarized in Table 2. The DAFNE
Dronedarone Atrial Fibrillation Study After Electrical
ardioversion) study was a phase 2 dose-ranging study that
stablished a 400 mg twice daily dose to have optimal
fficacy and safety (14). The EURIDIS (European Trial in
trial Fibrillation or Flutter Patients Receiving Dronedar-
ne for the Maintenance of Sinus Rhythm) and ADONIS
American-Australian Trial With Dronedarone in Atrial
Abbreviations
and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
bid  twice a day
CI  confidence interval
EF  ejection fraction
FDA  Food and Drug
Administration
NYHA  New York Heart
Association
RR  relative risk
ummary of Dronedarone TrialsTable 1 Summary of Dronedarone Trials
Trial Name Dose P
DAFNE (n  142) Dronedarone 400 to 800 mg bid vs. placebo Nonperm
EURIDIS (n  612) Dronedarone 400 mg bid vs. placebo Nonperm
ADONIS (n  625) Dronedarone 400 mg bid vs. placebo Nonperm
ERATO (n  174) Dronedarone 400 mg bid vs. placebo Perman
ANDROMEDA (n  627) Dronedarone 400 mg bid vs. placebo Worseni
ATHENA (n  4,628) Dronedarone 400 mg bid vs. placebo Stable (l
DIONYSOS (n  504) Dronedarone 400 mg bid vs.
amiodarone 200 mg
Nonperm
CM  all-cause mortality; ADONIS  American-Australian Trial With Dronedarone in Atrial Fibrilla
NDROMEDA  Antiarrhythmic Trial With Dronedarone in Moderate-to-Severe Congestive Heart Fa
ssess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalizati
ongestive heart failure; CV  cardiovascular; DAFNE  Dronedarone Atrial Fibrillation Study Afte
aintenance of Sinus Rhythm in Patients With Atrial Fibrillation); ERATO Efficacy and Safety of Droneda
ibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm.ibrillation or Flutter Patients for the Maintenance of Sinus
hythm) studies were identical sister trials performed under
he same protocol that assessed the efficacy of dronedarone
o maintain sinus rhythm in patients with a history of
onpermanent AF/AFL who were in sinus rhythm at the
ime of randomization and had no clinically significant
tructural heart disease or heart failure (15). Pooled data
rom these 2 studies demonstrated that at 12 months, 64%
f dronedarone-treated patients were estimated (Kaplan-
eier) to have experienced a first AF/AFL recurrence,
ompared with 75% of placebo-treated patients (p 0.001).
ata for symptomatic recurrence were 38% with droneda-
one and 46% with placebo (p 0.0003) (15). Although the
THENA (A Placebo-Controlled, Double-Blind, Parallel
rm Trial to Assess the Efficacy of Dronedarone 400 mg
id for the Prevention of Cardiovascular Hospitalization or
eath From Any Cause in Patients With Atrial Fibrilla-
ion/Atrial Flutter) study was designed to primarily evaluate
he impact of dronedarone on clinical outcomes, data on
rrhythmia recurrence were also assessed. In all 4 trials,
ronedarone delayed the time to the first recurrence of
rrhythmia and decreased recurrence of these events. Pooled
ata from all 4 studies are shown in Figure 1 and demonstrate
hat 43% of dronedarone-treated patients were estimated to
ave experienced a first AF/AFL recurrence, compared with
4% of placebo-treated patients (an absolute risk difference of
1%; number needed to treat  9; p  0.0001).
To put these findings into perspective, dronedarone is not
uch more effective than quinidine (50% efficacy in main-
aining sinus rhythm compared with 25% for placebo at 1
ear) (19). In contrast, a recent meta-analysis of 11 studies
nvolving a total of 5,044 patients reported a threefold
reater improvement in achieving and maintaining sinus
hythm with amiodarone compared with a placebo or
ate-control drug (20). Moreover, previous studies with
otalol and amiodarone have demonstrated attenuation of
reatment effect with longer follow-up (21–23). There is no
vidence to suggest that this might not be the case with
ronedarone as well. Thus, these data suggest that drone-
arone has modest antiarrhythmic efficacy.
ion Studied Mean Follow-Up Primary Efficacy End Point
AF/AFL (low risk) 6 months Time to recurrence of AF/AFL
AF/AFL (low risk) 12 months Time to recurrence of AF/AFL
AF/AFL (low risk) 12 months Time to recurrence of AF/AFL
(low risk) 6 months Rate control
(high risk) 13 months ACM or CHF hospitalization
moderate risk) 21 months ACM or CV hospitalization
t AF/AFL 6 months Recurrence of AF/AFL or discontinuation
due to intolerance
Flutter Patients for the Maintenance of Sinus Rhythm; AF  atrial fibrillation; AFL  atrial flutter;
aluating Morbidity Decrease; ATHENA  A Placebo-Controlled, Double-Blind, Parallel Arm Trial to
eath From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter; bid  twice a day; CHF 
rical Cardioversion; DIONYSOS  Efficacy and Safety of Dronedarone Versus Amiodarone for theopulat
anent
anent
anent
ent AF
ng CHF
ow to
anen
tion or
ilure Ev
on or D
r Electrone for the Control of Ventricular Rate During Atrial Fibrillation; EURIDIS European Trial in Atrial
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April 13, 2010:1569–76 Dronedarone for AFThe DIONYSOS (Efficacy and Safety of Dronedarone
ersus Amiodarone for the Maintenance of Sinus Rhythm
n Patients With Atrial Fibrillation) trial compared the
fficacy and safety of dronedarone (400 mg twice a day
bid]) versus amiodarone (600 mg daily for 28 days, then
00 mg daily thereafter) for at least 6 months for the
aintenance of sinus rhythm in patients with AF (12). The
rimary composite end point of AF recurrence or premature
rug discontinuation was reached in 74% of patients taking
ronedarone versus 55% of patients receiving amiodarone
p  0.001) (12). Description of the components of the
rimary end point showed that recurrences of AF were more
requent in the dronedarone group than in the amiodarone
roup (63% vs. 42%; relative risk [RR]: 1.51, 95% confi-
ence interval [CI]: 1.27 to 1.80) (Table 2), whereas
Antiarrhythmic Efficacy of DronedaroneTable 2 Antiarrhythmic Efficacy of Dronedar
Trial Dronedarone
DAFNE*
Time to recurrence, days 60
Recurrence rate 35/54 (65%)
EURIDIS
Time to recurrence, days 96
Recurrence rate 150/411 (37%)
ADONIS
Time to recurrence, days 158
Recurrence rate 154/417 (37%)
ATHENA
Time to recurrence, days 498
Recurrence rate 779/1,732 (45%)
DIONYSOS
Recurrence rate 158/249 (63%)
*Dronedarone dose 400 mg twice a day; time to recurrence is show
DIONYSOS study, where dronedarone was compared with amiodarone
Abbreviations as in Table 1.
Figure 1 RR of AF Recurrence With Dronedarone Versus Placeb
In a meta-analysis of relative risk of recurrence of atrial fibrillation (AF) treated with
used for pooling the data. Heterogeneity was assessed by Cochran’s Q and I2 tes
mate and extending to 95% confidence intervals (CIs). The squares and horizontal
squares is proportional to the weight of each study in the meta-analysis. See Tablremature study drug discontinuations due to intolerance were
ess frequent in the dronedarone group (10.4% vs. 13.3%; RR:
.78, 95% CI: 0.48 to 1.27 (24). Thus, dronedarone had a
tatistically significant 50% reduced efficacy in maintaining
inus rhythm (37% vs. 58%), while only being modestly, but
ot significantly, better tolerated than amiodarone (22% risk
eduction).
ate control. The ERATO (Efficacy and Safety of Drone-
arone for the Control of Ventricular Rate During Atrial
ibrillation) trial was a placebo-controlled study to evaluate
he efficacy of dronedarone 400 mg bid given for 6 months
n controlling the ventricular rate in patients with symp-
omatic permanent AF at rest (16). The primary end point,
ecrease from baseline in 24-h Holter heart rate on day 14,
as significantly more pronounced in the dronedarone
Control Risk Ratio p Value
5.32 0.45 (0.28–0.72) 0.001
43/48 (90%) 0.72 (0.58–0.90) 0.004
41 0.78 (0.64–0.96) 0.013
95/201 (47%) 0.77 (0.64–0.94) 0.009
59 0.73 (0.59–0.89) 0.002
89/208 (43%) 0.86 (0.71–1.06) 0.151
737 0.75 (0.65–0.87) 0.001
0/1,741 (55%) 0.75 (0.68–0.82) 0.001
07/255 (42%) 1.51 (1.27–1.80) 0.001
edian days. The control arm in all trials was placebo except for the
darone compared with placebo, a fixed effects (FE) Mantel-Haenszel model was
diamond shows the summary relative risk (RR) centered on a combined esti-
indicate RR and 95% CIs, respectively, for individual studies. The size of the
trial acronym definitions.one
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Dronedarone for AF April 13, 2010:1569–76roup (mean of 86.5 to 76.2 beats/min) than in the placebo
roup (90.6 to 90.2 beats/min) (16). This rate-controlling
ffect of dronedarone was sustained throughout the 6-month
rial and was additive to the effect of other rate-control
herapies. A similar pattern was seen among patients with AF
ecurrence in the DAFNE trial, where the mean ventricular
ate was lower with dronedarone 400 mg bid (89.7 vs. 102.9
eats/min, p  0.001) (14), the EURIDIS and ADONIS
rials (102 vs. 117 beats/min, p  0.001) (15), and the
THENA trial (75 vs. 84 beats/min, p  0.001) (18). These
ndings demonstrate that dronedarone reduces the ventricular
ate of patients with both permanent and nonpermanent AF.
Thus, in aggregate, these studies establish that droneda-
one has the ability to control both rhythm and rate in
atients with AF/AFL. However, the antiarrhythmic effi-
acy is quite modest compared with placebo and only half as
ffective compared with the gold standard amiodarone.
afety of Dronedarone
he safety of dronedarone has been evaluated in 2 random-
zed controlled trials. The ANDROMEDA (Antiarrhyth-
ic Trial With Dronedarone in Moderate-to-Severe Con-
estive Heart Failure Evaluating Morbidity Decrease) study
as designed to establish the safety in a vulnerable (high-
isk) population, whereas the ATHENA trial was per-
ormed to define a population for which dronedarone may
e safely used.
The ANDROMEDA trial enrolled patients with re-
ently symptomatic decompensated heart failure (New York
eart Association [NYHA] functional class II to IV) who
ay or may not have had AF (17). Approximately 25% and
7% of patients enrolled had AF on randomization or a
istory of AF, respectively. The primary end point was time
o mortality or hospitalization for worsening heart failure.
he trial was terminated prematurely after 650 (627 evalu-
ble cases) of a planned 1,000 were enrolled because of
xcess mortality among dronedarone-treated patients (17).
he excess mortality appeared to be predominantly related
o worsening heart failure, followed by arrhythmia and
udden death. The reason for excess mortality has been the
ubject of debate. Possible explanations include the follow-
ng: 1) a chance finding due to uncertainty related to
remature stopping of the trial; 2) a true finding related to
deleterious effect of dronedarone—mediated by its nega-
ive inotropic effect secondary to sodium-channel blockade,
eta-blockade, or adenylcyclase inhibition—in recently un-
table patients hospitalized for decompensated heart failure;
r 3) increased mortality due to inappropriate discontinua-
ion of angiotensin-converting enzyme inhibitor or
ngiotensin-receptor blocker as a result of dronedarone-
nduced inhibition of creatinine secretion. The latter is
nlikely, given that the relative risk of death among patients
ho never took or interrupted these medications appeared
o be higher (2 of 36 vs. 15 of 61; RR: 5.1, 95% CI: 1.16 to
2.2) compared with the overall ANDROMEDA study iopulation (RR: 2.3, 95% CI: 1.1 to 4.2) (12). The most
lausible explanation relates to the instability of patients
nrolled in the ANDROMEDA trial. The outcome of the
NDROMEDA study resulted in a nonapproval recom-
endation by the FDA, which indicated that approval
ould be reconsidered if efficacy and safety could be dem-
nstrated in a different and defined population.
The ATHENA study was a randomized trial to evaluate
he long-term effect of dronedarone 400 mg bid versus
lacebo on the combined risk of cardiovascular hospitaliza-
ion or all-cause mortality in patients with a recent or
urrent history of nonpermanent AF/AFL and additional
isk factors (18). The trial included 4,628 patients (making
t the largest antiarrhythmic trial ever conducted) with
85% with history of hypertension, 60% with structural
eart disease, and 31% with coronary artery disease. Al-
hough patients with stable heart failure were included, the
rial excluded patients who were clinically decompensated—
nly 21% of patients had NYHA functional class II or III
eart failure (none had class IV heart failure) and only 4%
ad left ventricular ejection fraction (EF) 0.35 compared
ith 100% of patients who had class II or greater heart
ailure in the ANDROMEDA study. Treatment with
ronedarone was associated with a 24% reduction of the
ombined risk of cardiovascular hospitalization or all cause-
eath (RR: 0.76, 95% CI: 0.69 to 0.84) compared with
lacebo over a follow-up of 21 months (18). Based largely
n the results of the ATHENA study, the FDA approved
ronedarone to reduce the risk of cardiovascular hospital-
zation in the treatment of AF/AFL.
There are several points regarding the ATHENA study
hat merit consideration. First, although it was 1 of the few
ntiarrhythmic trials to focus on hard clinical end points, the
ombined primary end point was primarily driven by car-
iovascular hospitalization, mostly related to AF or any
upraventricular arrhythmia. All-cause mortality was not
tatistically different (RR: 0.84, 95% CI: 0.66 to 1.08). The
pper bound of 1.08 indicates that a meaningful, namely,
8%, increase in the risk of death associated with drone-
arone was excluded. However, subgroup analysis revealed
hat the only subgroup for whom a clinically meaningful
ncrease in the risk of death was excluded was the clinically
table patients without AF/AFL on randomization (the
ajority of patients enrolled in ATHENA), with a hazard
atio of 0.81 (95% CI: 0.61 to 1.09). The upper bound of
he confidence interval was 1.21 for patients with EF35%
0.55 [95% CI: 0.25 to 1.21]), 1.34 in patients with NYHA
unctional class III heart failure (0.66 [95% CI: 0.32 to
.34]), 1.47 in patients with NYHA class I or II heart
ailure (0.93 [95% CI: 0.59 to 1.47), and 1.51 in stable
atients with AF/AFL on randomization, indicating that an
ncrease in mortality ranging from as high 21% to 51% could
ot be excluded in these patients (12,18). Taken together
ith the findings of the ANDROMEDA trial, these
bservations suggest that caution is warranted in consider-
ng dronedarone for patients who have heart failure in
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April 13, 2010:1569–76 Dronedarone for AFeneral, and that the use of dronedarone in patients with
YHA functional class IV heart failure or NYHA class II
r III heart failure with recently decompensated heart
ailure is contraindicated, resulting in a boxed warning by
he FDA (24).
Second, it is unclear why patients were hospitalized for
F, a key point relevant to clinical practice. Unlike the
NDROMEDA trial, the end points (including hospital-
zations) were not adjudicated by an external committee but
ere reported by the investigators. The information in the
nvestigator’s case report forms was incomplete and it did
ot capture whether patients were symptomatic, hemody-
amically unstable, had exacerbation of heart failure, or
equired anticoagulation therapy, all common indications
or hospitalizations for AF (12). Given that dronedarone
as a modest effect on AF recurrence and heart rate control,
t is unlikely that these would primarily account for reduced
ospitalizations. It is interesting to note that the favorable
rend in reduced heart failure hospitalizations with drone-
arone was not accompanied by symptomatic benefit in
atigue, dyspnea, and peripheral edema (12). That may well
e due to incomplete capture of information in the case
eport forms. Furthermore, dronedarone had no impact on
uality of life (as assessed by a survey tool)—an expected
eneficial outcome of reduced hospitalizations. However,
his was not systematically or properly evaluated during the
ntire course of the trial (12). Nonetheless, these observa-
ions raise questions about the quality of the data in the
THENA study and cast doubts on their relevance to
linical practice. Conversely, if reliably replicated in clinical
ractice, the potential reduction in cardiovascular hospital-
zations, especially the intensive care unit admissions, might
ave the potential for cost savings. However, at a retail cost
f $9 per day ($4.50 per 400 mg dose) or $3,285 per year,
t remains to be seen whether it will be cost effective
ompared with generic amiodarone.
Third, the quality of the data regarding cardiovascular
eath—a secondary end point that favored dronedarone (RR:
.70, p  0.037)—is suspect. The secondary end points were
rranged to be analyzed sequentially. The first secondary end
oint was all-cause mortality, which as noted in the preceding
ext, was not significantly lower with dronedarone, which
rguably precludes evaluation of subsequent end points of
ardiovascular death (or cardiovascular hospitalization alone).
he finding that the p value for cardiovascular death changed
rom being “not significant”—0.75 (95% CI: 0.54 to 1.04)—at
planned enrollment of 4,300 to being “significant”—0.71
95% CI: 0.51 to 0.98)—at extended enrollment of 4,637
arrants scrutiny (25). Moreover, lack of adjudication of events
ight introduce unreliability in the classification of the cause of
eath. Given these limitations, it is not surprising that the
DA did not allow a claim for cardiovascular or all-cause
ortality in favor of dronedarone as originally proposed by the
ponsor (24).
ooled analysis of morbidity and mortality. Pooled anal-
sis of 6 dronedarone trials involving a total of 6,771 eatients yielded no significant differences in the incidence of
ll-cause mortality or cardiovascular hospitalization com-
ared with placebo (Fig. 2A). There was significant statis-
ical as well as clinical heterogeneity, mostly attributable to
he ANDROMEDA trial, which recruited high-risk pa-
ients with recently decompensated heart failure. Accord-
ngly, in a sensitivity analysis that excludes the results of the
NDROMEDA study, use of dronedarone was associated
ith a 20% lower risk of the combined outcome (RR: 0.80,
5% CI: 0.74 to 0.86, heterogeneity p  0.09). Similarly,
ombining data from all 6 trials, the pooled estimates for
ll-cause mortality revealed a nonsignificant 5% decrease in
isk with dronedarone (Fig. 2B) (26). The upper bound of
.18 means that up to an 18% increase in mortality could
ot be excluded with dronedarone. The pooled estimate
xcluding the ANDROMEDA trial yielded an RR of 0.85
95% CI: 0.68 to 1.07), thereby excluding up to a 7%
ncrease in the risk of death with dronedarone. Thus, these
ata provide reassurance that dronedarone use is likely to be
afe for low-intermediate risk stable patients, namely, those
ithout recently decompensated heart failure or severe left
entricular dysfunction.
dverse Event Profile
he safety and tolerability of dronedarone has been well
haracterized in 3,200 patients with a mean follow-up of
pproximately 12 months. The main clinical adverse events
dentified with dronedarone are diarrhea, nausea or vomit-
ng, and rash. Dronedarone produces electrocardiographic
hanges consistent with its pharmacodynamic activity; there
s no evidence of a proarrhythmic effect of dronedarone,
ith only 1 case of torsades de pointes identified so far.
here is no deleterious impact on oral anticoagulation
herapy management. A benign transient increase in serum
reatinine (attributed to inhibition of renal tubular secre-
ion) has been observed with dronedarone that peaks at 7
ays and returns to baseline within 1 week after treatment
iscontinuation (15). Unlike amiodarone, dronedarone is not
ssociated with endocrinological, neurological, or pulmonary
oxicity in the pooled AF/AFL studies, although a mean
ollow-up of 12 months (21 months in the ATHENA study)
ay be an insufficient duration for observing the type of
ulmonary toxic effects seen with long-term amiodarone
se.
In the DIONYSOS study, which compared 400 mg bid
ronedarone with 200 mg amiodarone, dronedarone was
ssociated with a reduced risk of thyroid disorders, sleep
isorders, and tremor, and fewer episodes of bleeding due to
ess interference with oral anticoagulants, but the risk of
dverse gastrointestinal events was increased. However,
remature discontinuations due to treatment-related ad-
erse events (the primary tolerability end point) were not
tatistically different—10.4% versus 13.3% (RR: 0.78, 95%
I: 0.48 to 1.27) (12). Although no pulmonary or liver toxic
ffects were seen with either agent, the short duration (6
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Dronedarone for AF April 13, 2010:1569–76onths) of the study precludes any definitive conclusions
egarding long-term safety. Thus, while dronedarone has
een shown to be well tolerated compared with placebo,
hen compared with amiodarone, it has a modest, but
onsignificant, tolerability advantage. Long-term studies
re required to conclusively establish the superior safety and
olerability of dronedarone over amiodarone.
onclusions and Implications
he emergence of a new antiarrhythmic drug for AF/AFL
as been long awaited after the approval of dofetilide nearly
decade back (27). It is, therefore, no surprise that a great
eal of anticipation has surrounded the approval of drone-
Study Dronedarone Placebo
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Figure 2 RR of All-Cause Mortality or Cardiovascular Hospitaliz
and All-Cause Mortality Alone With Dronedarone Vers
In a meta-analysis of relative risk (RR) of all-cause mortality or cardiovascular (CV)
pared with placebo, a random effects (RE) DerSimonian-Laird model was used for
with continuity correction for zero events (26) was used for pooling the all-cause m
shows the summary RR centered on a combined estimate and extending to 95% c
respectively, for individual studies. The size of the squares is proportional to the warone. Envisioned as a safer alternative to amiodarone for maintaining sinus rhythm in patients with AF, dronedarone
ay also lower the risk of some clinical outcomes. However,
ts relatively modest efficacy in preventing AF/AFL recur-
ence or rate control as well as questions regarding its short-
nd long-term safety in at-risk patients leave its role in the
anagement of this arrhythmia uncertain.
What role do we see for this drug in clinical practice? In
eneral, based on available evidence, it is difficult to support
n approach to rhythm control in most patients with AF
ithout first trying a rate-control strategy. Treatment with
ntiarrhythmic drugs should generally be considered only
hen symptoms persist despite adequate rate control. When
rhythm-control strategy is desired for patients with no or
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April 13, 2010:1569–76 Dronedarone for AFut without substantial left ventricular hypertrophy, flecain-
de, propafenone, and sotalol are recommended as first-line
gents by guidelines (28) based on their proven safety and
fficacy in this population (Fig. 3). The use of dronedarone
ight merit consideration for these patients as an alterna-
ive to amiodarone or dofetilide (recommended as second-
ine agents), especially for patients intolerant to these drugs.
or patients with hypertension and substantial left ventric-
lar hypertrophy, amiodarone should be used as first-line
reatment (28) with consideration for dronedarone only for
atients who are intolerant of amiodarone. For patients with
oronary artery disease and without overt heart failure, for
hom dofetilide and sotalol are recommended as first-line
reatment option (28), dronedarone might be a reason-
ble alternative to these drugs or to amiodarone (second-
ine therapy). Among patients with heart failure (repre-
enting a sizeable group with this arrhythmia) for whom
rhythm-control strategy is desired, amiodarone or
ofetilide is recommended as a first-line agent based on
ts neutral effect on survival in these patients. In general,
Figure 3 Potential Role for Dronedarone in AF
The flow chart illustrates the potential role for dronedarone in guideline-recommen
(AF). *Dronedarone as a reasonable alternative for patients intolerant of first-line t
lar hypertrophy; NYHA  New York Heart Association.ronedarone should be avoided in patients with heart wailure, especially those with advanced or recently decom-
ensated heart failure (more than NYHA functional class
I, or EF 35% [ANDROMEDA-type patients]) for
hich it carries a “boxed” warning. However, for patients
ith less advanced and without recently (within the last
onth) decompensated heart failure (NYHA functional
lass II or less, or EF 35% [ATHENA-type patients]),
ronedarone could potentially offer a reasonable alterna-
ive, particularly for patients who are intolerant of low-
ose amiodarone or dofetilide. For patients falling be-
ween the ANDROMEDA and ATHENA study
opulations, the benefit-risk profile of dronedarone is unclear.
hus, the available data support only limited use of
ronedarone for select patient populations, mostly as a
econd- or third-line agent in lieu of amiodarone.
Although the drug has been approved to reduce cardio-
ascular hospitalizations related to AF/AFL in a restricted
atient population (low-intermediate risk patients with
urrent or previous history of nonpermanent AF/AFL but
ithout advanced or recently decompensated heart failure),
atment for the maintenance of sinus rhythm in patients with atrial fibrillation
ent. Adapted from Fuster et al. (28). EF  ejection fraction; LVH  left ventricu-ded tre
reatme anticipate that, in clinical practice, it will likely be used
f
a
e
j
a
u
i
w
s
d
n
i
r
h
m
A
T
P
a
r
R
o
l
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
K
1576 Singh et al. JACC Vol. 55, No. 15, 2010
Dronedarone for AF April 13, 2010:1569–76or a broader population and for indications beyond its
pproved label. Although we recognize that reconciling
fficacy versus safety is ultimately a matter of clinical
udgment and patient preference, we nevertheless caution
gainst the indiscriminate use of dronedarone. To further
nderstand how dronedarone will fare against amiodarone
n the wider population with heart disease, more studies
ith longer follow-up are needed. At the very least, these
tudies need to demonstrate superior tolerability of drone-
arone without unacceptable loss of efficacy in the mainte-
ance of sinus rhythm and quality of life, or without an
ncrease in morbidity or mortality compared with amioda-
one. Until then, dronedarone may be best viewed only as
alf a step forward in our efforts to expand the antiarrhyth-
ic armamentarium.
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